Huang, J, Tan, KS, Altorki, N, Antonoff, MB , Blackmon, SH, Bueno, R, Burt, BM, Demmy, TL, Evans, N, Donahoe, L, Harpole, DH, Jarrar, D, Kozower, BD, Lanuti, M, Liberman, M, Lin, J, Liou, D, Liptay, MJ, Luketich, J, Pennathur, A, Petersen, G, Ripley, RT, Rochefort, M, Seder, CW, Shrager, JB, Su, S, Tong, BC, Shargall, Y, Vaporciyan, AA, Waddell, TK, Weksler, B, Wigle, DA, Yendamuri, S, Jones, DR
A kinetic analysis of the reactions of hypobromous acid with protein components: implications for cellular damage and the use of 3-bromotyrosine as a marker of oxidative stress
doi: 10.3389/fimmu.2026.1758379 Received 01 December 2025 Revised 05 March 2026 Accepted 05 March 2026 Published 28 April 2026 Volume 17 - 2026 Edited by Varun Sasidharan Nair, Italian Institute of Technology (IIT), Italy Reviewed by Mahmoud Abdelrahman Alkabbani, Egyptian Russian University, Egypt Lingjie Meng, Zunyi Medical University, China Updates Copyright 2026 Sivalingam
Therapeutic Opportunities With Pharmacological Inhibition of CD38 With Isatuximab
To understand what causes unhealthy aging, scientific research has identified nine hallmark defects which are believed to contribute to the aging process
Dosage Guidelines by Treatment Goal Acute injury recovery: 500750mcg daily for 24 weeks Chronic condition management: 250500mcg daily for 612 weeks Gut health support: 250500mcg daily for 48 weeks General wellness and prevention: 200300mcg daily, 5 days per week Important: Always consult with a healthcare provider before starting BPC-157 therapy
